WordNet

a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
a protein present in blood plasma; converts to fibrin when blood clots (同)factor_I

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

RUC-4: A Novel αIIbβ3 Antagonist for Prehospital Therapy of Myocardial Infarction.

Li J1, Vootukuri S1, Shang Y1, Negri A1, Jiang JK1, Nedelman M1, Diacovo TG1, Filizola M1, Thomas CJ1, Coller BS2.
Arteriosclerosis, thrombosis, and vascular biology.Arterioscler Thromb Vasc Biol.2014 Oct;34(10):2321-9. doi: 10.1161/ATVBAHA.114.303724. Epub 2014 Aug 21.
OBJECTIVE: Treatment of myocardial infarction within the first 1 to 2 hours with a thrombolytic agent, percutaneous coronary intervention, or an αIIbβ3 antagonist decreases mortality and the later development of heart failure. We previously reported on a novel small molecule αIIbβ3 antagonist, R
PMID 25147334

Vaish A1, Vanderah DJ2, Vierling R3, Crawshaw F3, Gallagher DT3, Walker ML4.
Colloids and surfaces. B, Biointerfaces.Colloids Surf B Biointerfaces.2014 Oct 1;122:552-8. doi: 10.1016/j.colsurfb.2014.07.031. Epub 2014 Jul 31.
As part of an effort to develop biointerfaces for structure-function studies of integral membrane proteins (IMPs) a series of oligo(ethylene oxide) self-assembled monolayers (OEO-SAMs) were evaluated for their resistance to protein adsorption (RPA) of IMPs on Au and Pt. Spectroscopic ellipsometry (S
PMID 25124834

Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.

Ross Eckard A1, Longenecker C, Jiang Y, Debanne S, Labbato D, Storer N, McComsey G.
HIV medicine.HIV Med.2014 Oct;15(9):537-46. doi: 10.1111/hiv.12143. Epub 2014 Mar 20.
OBJECTIVES: HIV-infected patients on antiretroviral therapy (ART) have an increased cardiovascular disease (CVD) risk as a result of heightened inflammation and immune activation, despite at times having normal lipids and few traditional risk factors. Biomarkers are needed to identify such patients
PMID 24650269

朝倉伸司,佐々木廉雄,足助雄二 [他],渡辺弘規,加賀誠,清水ひろえ,川田松江,播磨晋太郎,長濱裕,松田道生
日本透析医学会雑誌 = Journal of Japanese Society for Dialysis Therapy 42(12), 947-953, 2009-12-28
… するRGDドメインがフィブリンモノマーのE領域表面に露呈されること，また，これが細胞膜に存在し，フィブリノゲン受容体（fibrinogen receptor）として働くα5β1インテグリンおよびビトロネクチン受容体（vitronectin receptor）であるαvβ3をも巻き込みながら細胞伸展を促進することをわれわれはすでに報告しており，SFが単に血液凝 …
NAID 10026315970

波多江健,小野山さがの,宗秀典,緒方怜奈,原田達生,土本晃裕,平方秀樹,片渕律子,藤野歩
日本小児腎臓病学会雑誌 = Japanese journal of pediatric nephrology 20(2), 220-225, 2007-11-15
… 蛍光抗体法ではIgG，IgA，C3，Fibrinogenが係蹄壁に強く沈着していた。 …
NAID 10025701339

Recent Advances in Immunopathophysiology of Interleukin-6 : An Innovative Therapeutic Drug, Tocilizumab (Recombinant Humanized Anti-human Interleukin-6 Receptor Antibody), Unveils The Mysterious Etiology of Immune-Mediated Inflammatory Diseases

Ohsugi Yoshiyuki
Biological & pharmaceutical bulletin 30(11), 2001-2006, 2007-11-01
… From the clinical viewpoint, it is especially important that IL-6 acts on hepatocytes to induce acute-phase reactants, including C-reactive protein, serum amyloid A protein, and fibrinogen, and to decrease serum albumin levels. … In practice, blocking the IL-6 signaling pathway with a recombinant humanized anti-IL-6 receptor antibody, tocilizumab (TCZ), has dramatically improved all the signs and symptoms of these patients. …
NAID 110006473473